Outcomes registry for better informed treatment of atrial fibrillation: Rationale and design of ORBIT-AF
Jonathan P. Piccini(Clinical Research Institute), Eric D. Peterson(The University of Texas Southwestern Medical Center), Melissa H. Kong(Durham University), Elizabeth Fraulo(Durham University), Alan S. Go(Kaiser Permanente), Kenneth W. Mahaffey(Cardiovascular Institute of the South), Laine Thomas(Duke University), Roger M. Mills(Janssen (Belgium)), Renato D. Lópes(Duke University), Gregg C. Fonarow(UCLA Medical Center), Bernard J. Gersh(Clinical Research Institute), Peter R. Kowey(Lankenau Institute for Medical Research), Elaine M. Hylek(Boston University), Jack Ansell(Hofstra University)
Cited by 147
Related Papers
Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization
|New England Journal of Medicine|2004|11.4k
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k